Running title: Radiation dosimetry for 177Lu-PSMA I&T
INTRODUCTION
Prostate cancer (PC) is the second most common cancer in men worldwide (1) . About 30% of men experience biochemical recurrence often followed by progression to mCRPC. Despite several treatment options for these patients more than 250,000 men are still dying from PC worldwide each year (1) . Most recently PSMA is gaining significant interest as a target for imaging as well as radionuclide therapy (2, 3) . Its expression correlates with the malignancy of the disease, being further increased in mCRPC (4) . A variety of PSMA-ligands for RLT have been developed in recent years (for an overview, see (5) ). Several studies using 131 I or 177 Lu labelled PSMA-ligands for RLT reported reductions in tumor volume and serum prostate-specific antigen (PSA) levels (3, (6) (7) (8) (9) (10) . For the assessment of a new radiopharmaceutical dosimetry is essential to aim for the optimal therapeutic response with limited side effects. Beside the high and specific uptake of PSMA-ligands in prostate cancer tissue, different normal organs (e.g. kidney, salivary glands, proximal intestine) exhibit tracer accumulation. Recently published studies using the theranostic DOTA-conjugated PSMA-ligand agent have been published recently (10). Similar results on clinical efficacy were reported by Baum et al. with additionally data on dosimetry (7). In peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors high tumor uptake in pre-therapeutic PET and high tumor-absorbed dose are regarded to be predictive of the therapeutic success (14) . The standardized uptake value (SUV) may serve as indicator for later-achieved absorbed dose (15) (16) (17) . Presumably also in mCRPC decision for or against RLT may be influenced and eventually potentially based on pre-therapeutic PET.
Thus, the purpose of this study was to estimate the absorbed doses for 
MATERIALS AND METHODS

Patients And 68
Ga-PSMA-HEBD-CC PET/CT.
Between January 2015 and March 2016, 18 patients (Table 1) with mCRPC and PSMAavid lesions on pre-therapeutic PET underwent a total of 34 cycles 177 Lu-PSMA-I&T (n=15 for first, n=9 for second, n=5 for third, n=5 for fourth cycle) using a reference activity of 7.4 GBq combined with a dedicated protocol for post-therapy dosimetry. The institutional review board of the Technische Universität München approved this study and all subjects signed a written informed consent.
177
Lu-PSMA-I&T RLT And Post-therapy Scintigraphy.
Mean applied activity for all cycles was 7.3±0.30 GBq (range: 6.47-7.83), 7.3±0.32 GBq (range: 6.47-7.78) for the first cycle, 7.3±0.34 GBq (range: 6.47-7.73), for the second cycle, 7.5±0.22 GBq (range: 7.30-7.83) for the third cycle, and 7.3±0.24 GBq (range: 6.95-7.60) for the fourth cycle. Whole-body scintigraphy was performed at least between 30-120 minutes, 24 hours and 6-8 days after administration of 177 Lu-PSMA I&T. In some cycles (n=8) patients also underwent whole-body scintigraphy 48 and 72 hour after the tracer injection (p.i.). In detail, 26 cycles were analyzed with 3, 2 cycles with 4 and 6 cycles with 5 post-therapy scintigraphies, respectively. Details on the synthesis, application and post-therapy scintigraphy of 177 Lu-PSMA-I&T is given in supplemental "Material and Methods".
Image Analysis.
Individual patient absorbed doses for whole body, kidneys, liver, parotid, submandibular glands and lacrimal glands were estimated based on the Medical Internal Radiation Dose scheme and as recommended in the European Association of Nuclear Medicine Dosimetry Committee Guidelines (18, 19) . Regions of interest (ROIs) on whole body, kidneys, liver, parotid glands, submandibular glands and lacrimal glands and up to 4 tumor lesions were delineated manually on the anterior and posterior whole-body images at 24 hours p.i. by two experienced nuclear medicine physicians and then manually relocated on the previous and subsequent scans (Figure 1 ). The volume of normal organs and tumor lesions were calculated using the CT-dataset of the corresponding pre-therapeutic Table 2 ). Details on the ROIs for scintigraphy as well as volume calculation in CT is given in supplemental "Material and Methods". Statistical Analysis.
All continuous data reported are expressed as mean, standard deviation and range. Twosample t tests were used to evaluate differences between individual groups. Correlations between SUVs, change of SUV between pre-and post-therapeutic PET (ΔSUV) and absorbed dose in tumor lesions were assessed using Spearman's rank correlation coefficient. A significance level of α=5% was used. Statistical analyses were conducted using MedCalc (version 13.2.0, 2014; MedCalc, Ostend, Belgium).
RESULTS
Qualitative 177
Lu-PSMA-I&T Distribution On Post-therapeutic Scintigraphy.
Physiological uptake was seen in lacrimal, parotid and submandibular glands, kidneys, small intestine and less pronounced in liver and spleen. Uptake in excess of background was also seen for multiple tumor lesions with progressive accumulation up to 24-48 h after injection ( Figure   1 ). Delayed whole-body images (up to 6-8 days post-therapy) exhibited long-term retention of 177 Lu-PSMA-I&T in the metastases with nearly no residual uptake in normal organs. Dosimetry For Normal Organs.
The mean whole body effective dose for all cycles was 0.41± 0.18 Sv (0.06 Sv/GBq).
Mean absorbed organ doses were 5.3±1.6 Gy (0.72 Gy/GBq) for the kidneys, 0.89±0.42 Gy (0.12 Gy/GBq) for the liver, 4.0±1.1 Gy (0.55 Gy/GBq) for parotid glands, 4.8±2.8 Gy (0.64 Gy/GBq) for submandibular glands, 27±10 Gy (3.8 Gy/GBq) for lacrimal glands. The values (mean, standard deviation and ranges) for the corresponding absorbed doses per GBq are presented in Table 1 . No substantial difference for absorbed doses of normal organs were observed when comparing them with respect to cycle number (Table 1 and In total, all lesions received a mean dose per cycle of 23±20 Gy (3.3 Gy/GBq). Mean absorbed dose for bone, lymph node, liver, and lung metastases were 26±20 Gy (3.4 Gy/GBq), 24±16 Gy (3.2 Gy/GBq), 8.5±4.7 Gy (1.28 Gy/GBq), and 13±7.4 Gy (1.7 Gy/GBq). The values (mean, standard deviation and range) for the corresponding absorbed doses per GBq are presented in Table 2 . Figure 2 shows the mean absorbed dose in all tumor lesions with respect to the specific therapy cycle. Figure 3 shows a representative example of a patient with a histologically proven lung metastasis and multiple bone metastases. There is a clear trend towards a lower absorbed dose with an increasing number of the cycle. Mean absorbed dose per lesion was 26±21 Gy (3.5 Gy/GBq) for the first, 24±19 Gy (3.3 Gy/GBq) for the second, 20±18 Gy (2.7 Gy/GBq) for the third and 18±17 Gy (2.4 Gy/GBq) for the fourth cycle. A similar trend can be seen for the subgroup of bone metastases. No reliable comparison is possible for lymph node, liver and lung metastases due to a low sample number.
Correlation Of SUV And Absorbed Doses In Tumor Lesions.
The mean SUVmax and mean SUVmean of all lesions in pre-therapeutic PET were 22±14 (range: 3.5-64.8) and 15±10 (range: 2.4-46.8), respectively (supplementary Table 2 
DISCUSSION
We present data for radiation dosimetry for normal organs and tumor lesions using Lu-PSMA-DKFZ-617 it has been shown that (mainly) over-estimation of doses is present when omitting the late time point (mean 9.8% for whole body, 22.0% for kidney, 19.4% for salivary glands, 10.6% lacrimal glands) (12) .
In several radio-receptor therapies the kidney is regarded as the dose limiting organ (21). Our results for kidneys (mean 0.72 Gy/GBq) are well comparable to a recent publication using the same radiopharmaceutical (kidney: median 0.8 Gy/GBq) (7). For Table 2 ). In PRRT this has also been reported for the use of fits into the concept that with a higher target expression a higher molecular response can be expected. Nevertheless, the missing correlation between absorbed dose and change of SUV (ΔSUV) indicates that besides target expression other factors of tumor biology are present for determination of therapy response. In addition, it has to be taken into account that more sophisticated approaches exist which can be used to predict the therapeutic biodistribution. E.g.
Hardiansyah et al. recently presented a so-called physiologically based pharmacokinetic model
which aims for individualization of treatment planned and integrates a variety of patient specific data (e.g., weight, tumor volume, and glomerular filtration rate) (26).
With the kidneys being the relevant critical organ our data indicate that in average a cumulative activity of 40 GBq 177 Lu-PSMA-I&T is safe when taken 28 Gy (50% probability of developing severe late kidney damage within 5 years) as dose limit (27). With respect to the average life expectancy of mCRPC patients this approach seems to be justifiable. This would allow at least five cycles using 7.4 GBq GBq to achieve 23 Gy kidney dose (13) . Nevertheless these absorbed dose limits are based on the conventionally fractionated external beam therapy and cannot necessarily be directly applied to low dose-rate radiation (28). Patients without risk factors for kidney disease might tolerate a renal biological equivalent dose up to 40 Gy, based on experience in NET (29).
There are several limitations of our study. First, the different peptides used for PET on one hand (PSMA-HBED-CC) and therapy on the other (PSMA I&T) is noteworthy. Second, one principal bias of dosimetry studies is the selection of tumor lesions that show better delineation from the surrounding healthy tissue and thus a relatively high absorbed dose. Numerous factors can impair the accuracy of PET and planar dosimetry and can lead to decreased correlation of the two modalities. Overlay in planar scintigraphy can lead to an overestimation of dose (11, 20) .
Single-photon-emission-computed/tomography should be the method of choice to avoid overlap with physiological uptake and tumor uptake. Potential additional errors can occur both for volumetric assessment and measurement of SUV for the tumor lesions. We tried to minimize this error, by adjusting a volume-of-interest using information from PET best to the anatomical configuration of the lesions. However, especially for bone lesions, the anatomical delineation can be difficult. On the other hand SUVmax (as compared to SUVmean) is a highly reproducible metric with small expected error for quantification is in the range of up to 10% (30,31). Third, we have not applied any sophisticated model in this study to aim for individual treatment planning.
Fourth, it has to be stressed that the data comparing absorbed doses in different treatment cycles are not only based on the same patients.
Conclusion
Organ and tumor absorbed doses for A: Absorbed dose for lung metastasis for 1st, 2nd and 3rd cycle were 20.9 Gy, 9.7 Gy and 6.9
Gy, respectively. B. SUVmax and SUVmean on pre-therapeutic PET at each cycle were 21.2, 9.9 and 3.7, and 13.8, 6.6 and 2.5 respectively. 
